Literature DB >> 22245904

Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review.

Kirsten Boonstra1, Ulrich Beuers, Cyriel Y Ponsioen.   

Abstract

OBJECTIVE: Studies on the epidemiology of primary sclerosing cholangitis (PSC) and primary biliary cirrhosis (PBC) show variable outcome. We aimed at systematically reviewing the incidence and prevalence rates, as well as geographical distribution and temporal trends of PSC and PBC. DATA SOURCES: A systematic search of literature was performed in Medline and EMBASE (search last conducted January 10th, 2011). STUDY SELECTION: Population-based epidemiological studies reporting incidence and/or prevalence rates for PSC or PBC in a defined geographical area of at least 100,000 adult inhabitants were considered relevant. DATA EXTRACTION: Study area, study period, number of patients, number of inhabitants, incidence per 100,000 inhabitants per year, prevalence per 100,000 inhabitants, method of case-finding, method of case-ascertainment, male/female ratio and in case of PSC, occurrence of inflammatory bowel diseases (IBD) were extracted from retrieved articles.
RESULTS: The literature search yielded 2286 abstracts of which 31 articles fulfilled all inclusion criteria. Studies varied in size from 10 to 770 patients in catchment areas from 100,312 to 19,230,000 inhabitants. The incidence and prevalence rates for PSC range from 0 to 1.3 per 100,000 inhabitants/year and 0-16.2 per 100,000 inhabitants, respectively. PBC incidence rates range from 0.33 to 5.8 per 100,000 inhabitants/year and prevalence rates range from 1.91 to 40.2 per 100,000 inhabitants; prevalence rates are increasing in time.
CONCLUSIONS: Incidence and prevalence rates of both PSC and PBC vary widely and seem to be increasing. True population-based studies are scarce and therefore large population-based studies combining meticulous case-finding and case-ascertainment strategies are necessary. Copyright Â
© 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22245904     DOI: 10.1016/j.jhep.2011.10.025

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  146 in total

Review 1.  Primary biliary cirrhosis: From bench to bedside.

Authors:  Elias Kouroumalis; George Notas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-08-06

2.  Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study.

Authors:  John E Eaton; Kevin M Nelson; Andrea A Gossard; Elizabeth J Carey; James H Tabibian; Keith D Lindor; Nicholas F LaRusso
Journal:  Scand J Gastroenterol       Date:  2019-05-26       Impact factor: 2.423

Review 3.  [Chronic cholestatic liver diseases : Differential diagnosis, pathogenesis and current treatment in adults].

Authors:  S Hohenester; U Beuers
Journal:  Internist (Berl)       Date:  2017-08       Impact factor: 0.743

4.  Gene-disease associations identify a connectome with shared molecular pathways in human cholangiopathies.

Authors:  Zhenhua Luo; Anil G Jegga; Jorge A Bezerra
Journal:  Hepatology       Date:  2018-01-02       Impact factor: 17.425

Review 5.  Sex-related factors in autoimmune liver diseases.

Authors:  Dorothee Schwinge; Christoph Schramm
Journal:  Semin Immunopathol       Date:  2018-10-01       Impact factor: 9.623

6.  Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.

Authors:  Angela C Cheung; Nicholas F LaRusso; Gregory J Gores; Konstantinos N Lazaridis
Journal:  Semin Liver Dis       Date:  2017-05-31       Impact factor: 6.115

7.  Cholestatic liver disease results increased production of reactive aldehydes and an atypical periportal hepatic antioxidant response.

Authors:  Colin T Shearn; Blair Fennimore; David J Orlicky; Yue R Gao; Laura M Saba; Kayla D Battista; Stefanos Aivazidis; Mohammed Assiri; Peter S Harris; Cole Michel; Gary F Merrill; Edward E Schmidt; Sean P Colgan; Dennis R Petersen
Journal:  Free Radic Biol Med       Date:  2019-08-01       Impact factor: 7.376

8.  MiR-139-5p is associated with inflammatory regulation through c-FOS suppression, and contributes to the progression of primary biliary cholangitis.

Authors:  Tomohiro Katsumi; Masashi Ninomiya; Taketo Nishina; Kei Mizuno; Kyoko Tomita; Hiroaki Haga; Kazuo Okumoto; Takafumi Saito; Tooru Shimosegawa; Yoshiyuki Ueno
Journal:  Lab Invest       Date:  2016-09-26       Impact factor: 5.662

9.  Micro-computed tomography and nuclear magnetic resonance imaging for noninvasive, live-mouse cholangiography.

Authors:  James H Tabibian; Slobodan I Macura; Steven P O'Hara; Jeff L Fidler; James F Glockner; Naoki Takahashi; Val J Lowe; Bradley J Kemp; Prasanna K Mishra; Pamela S Tietz; Patrick L Splinter; Christy E Trussoni; Nicholas F LaRusso
Journal:  Lab Invest       Date:  2013-04-15       Impact factor: 5.662

Review 10.  The genetics of complex cholestatic disorders.

Authors:  Gideon M Hirschfield; Roger W Chapman; Tom H Karlsen; Frank Lammert; Konstantinos N Lazaridis; Andrew L Mason
Journal:  Gastroenterology       Date:  2013-04-10       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.